Arginine-Rich Manganese Silicate Nanobubbles as a Ferroptosis-Inducing Agent for Tumor-Targeted Theranostics

Wang, Shuaifei; Li, Fangyuan; Qiao, Ruirui; Hu, Xi; Liao, Hongwei; Chen, Lumin; Wu, Jiahe; Wu, Haibin; Zhao, Meng; Liu, Jianan; Chen, Rui; Ma, Xibo; Kim, Dokyoon; Sun, Jihong; Davis, Thomas P.; Chen, Chunying; Tian, Jie; Hyeon, Taeghwan; Ling, Daishun

doi:10.1021/acsnano.8b06399

Cited by 335 publications

(216 citation statements)

References 62 publications

Supporting

Mentioning

214

Contrasting

Order By: Relevance

“…Upon erastin treatment, the intracellular ROS level increased in a time‐dependent manner (Figure C–E). The basal ROS levels can be measured with cytosolic fluorescent ROS sensors, such as 2′,7′‐dichlorodihydrofluorescein diacetate (H2DCFDA) . Mitochondrial ROS can be detected with red fluorescent probe MitoSOX .…”

Section: Basis Of Ferroptosismentioning

confidence: 99%

See 1 more Smart Citation

Recent Progress in Ferroptosis Inducers for Cancer Therapy

et al. 2019

View full text Add to dashboard Cite

Ferroptosis is a newly discovered form of regulated cell death that is the nexus between metabolism, redox biology, and human health. Emerging evidence shows the potential of triggering ferroptosis for cancer therapy, particularly for eradicating aggressive malignancies that are resistant to traditional therapies. Recently, there has been a great deal of effort to design and develop anticancer drugs based on ferroptosis induction. Recent advances of ferroptosis‐inducing agents at the intersection of chemistry, materials science, and cancer biology are presented. The basis of ferroptosis is summarized first to highlight the feasibility and characteristics of triggering ferroptosis for cancer therapy. A literature review of ferroptosis inducers (including small molecules and nanomaterials) is then presented to delineate their design, action mechanisms, and anticancer applications. Finally, some considerations for research on ferroptosis inducers are spotlighted, followed by a discussion on the challenges and future development directions of this burgeoning field.

show abstract

Section: Basis Of Ferroptosismentioning

confidence: 99%

Section: Ferroptosis Inducers For Cancer Therapymentioning

confidence: 99%

Recent Progress in Ferroptosis Inducers for Cancer Therapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In addition, many nanoparticles, such as zero-valent iron nanoparticles and arginine-rich manganese silicate nanobubbles, induce ferroptosis in cancer cells depending on the nanoparticle structure and chemical modifications [164][165][166][167]. Similarly, nanoparticles trigger necroptotic tumor cell death by modulating autophagy [168].…”

Section: Ferroptosis/ Necroptosismentioning

confidence: 99%

Ferroptosis, necroptosis, and pyroptosis in anticancer immunity

et al. 2020

View full text Add to dashboard Cite

In recent years, cancer immunotherapy based on immune checkpoint inhibitors (ICIs) has achieved considerable success in the clinic. However, ICIs are significantly limited by the fact that only one third of patients with most types of cancer respond to these agents. The induction of cell death mechanisms other than apoptosis has gradually emerged as a new cancer treatment strategy because most tumors harbor innate resistance to apoptosis. However, to date, the possibility of combining these two modalities has not been discussed systematically. Recently, a few studies revealed crosstalk between distinct cell death mechanisms and antitumor immunity. The induction of pyroptosis, ferroptosis, and necroptosis combined with ICIs showed synergistically enhanced antitumor activity, even in ICI-resistant tumors. Immunotherapy-activated CD8+ T cells are traditionally believed to induce tumor cell death via the following two main pathways: (i) perforin-granzyme and (ii) Fas-FasL. However, recent studies identified a new mechanism by which CD8+ T cells suppress tumor growth by inducing ferroptosis and pyroptosis, which provoked a review of the relationship between tumor cell death mechanisms and immune system activation. Hence, in this review, we summarize knowledge of the reciprocal interaction between antitumor immunity and distinct cell death mechanisms, particularly necroptosis, ferroptosis, and pyroptosis, which are the three potentially novel mechanisms of immunogenic cell death. Because most evidence is derived from studies using animal and cell models, we also reviewed related bioinformatics data available for human tissues in public databases, which partially confirmed the presence of interactions between tumor cell death and the activation of antitumor immunity.

show abstract

Section: Therapeutic Applicationsmentioning

confidence: 99%

Manganese Oxide Nanomaterials: Synthesis, Properties, and Theranostic Applications

et al. 2020

View full text Add to dashboard Cite

Despite the comprehensive applications in bioimaging, biosensing, drug/gene delivery, and tumor therapy of manganese oxide nanomaterials (MONs including MnO2, MnO, Mn2O3, Mn3O4, and MnOx) and their derivatives, a review article focusing on MON‐based nanoplatforms has not been reported yet. Herein, the representative progresses of MONs on synthesis, heterogene, properties, surface modification, toxicity, imaging, biodetection, and therapy are mainly introduced. First, five kinds of primary synthetic methods of MONs are presented, including thermal decomposition method, exfoliation strategy, permanganates reduction method, adsorption–oxidation method, and hydro/solvothermal. Second, the preparations of hollow MONs and MON‐based composite materials are summarized specially. Then, the chemical properties, surface modification, and toxicity of MONs are discussed. Next, the diagnostic applications including imaging and sensing are outlined. Finally, some representative rational designs of MONs in photodynamic therapy, photothermal therapy, chemodynamic therapy, sonodynamic therapy, radiotherapy, magnetic hyperthermia, chemotherapy, gene therapy, starvation therapy, ferroptosis, immunotherapy, and various combination therapy are highlighted.

show abstract

Arginine-Rich Manganese Silicate Nanobubbles as a Ferroptosis-Inducing Agent for Tumor-Targeted Theranostics

Cited by 335 publications

References 62 publications

Recent Progress in Ferroptosis Inducers for Cancer Therapy

Recent Progress in Ferroptosis Inducers for Cancer Therapy

Ferroptosis, necroptosis, and pyroptosis in anticancer immunity

Manganese Oxide Nanomaterials: Synthesis, Properties, and Theranostic Applications

Contact Info

Product

Resources

About